| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:679.)
© 2003 American Heart Association, Inc.
Brief Rapid Communications |
From Internal Medicine I, National Defense Medical College (K.I., Y.K., M.A., M.K., F.O.), Tokorozawa, Japan, and the Division of Biomedical Research Resources, Juntendo University School of Medicine (N.T.), Tokyo, Japan.
Correspondence to Kikuo Isoda, MD, PhD, Internal Medicine I, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama, 359-8513, Japan. E-mail isoda{at}me.ndmc.ac.jp
| Abstract |
|---|
|
|
|---|
Methods and Results We investigated the contribution of OPN to atherosclerosis by evaluating aortic sinus lesions of both OPN transgenic (Tg) and non-Tg mice fed an atherogenic diet (1.25% cholesterol) for 16 weeks. The atherosclerotic lesions were found to be significantly larger in OPN-Tg compared with those in non-Tg (17 859±2010 versus 6469±485 µm2, P<0.01). The lesions in both mice were fatty-streak lesions with an accumulation of mononuclear cells and lipids. We next investigated the production of interleukin (IL)-10 by macrophages from both mice. Compared with the non-Tg mice, a 42% (P<0.01) and 73% (P<0.001) decrease in the IL-10 production was identified in the OPN-Tg mice either without or with lipopolysaccharide.
Conclusions The expression of OPN induces fatty-streak lesion formation in mice fed an atherogenic diet and inhibits IL-10 production by macrophages, thus suggesting that OPN plays an important role in the development of fatty-streak lesions in vivo.
Key Words: atherosclerosis genes interleukins
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Plasma Lipid Measurements
On the day of analysis, food was removed from the cages in the morning, and the mice were fasted for 7 hours. The plasma total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels were then measured by enzymatic assays as previously described.6
Quantification of Aortic Sinus Lesions
The sections containing aortic sinus were prepared as previously reported,7 with modifications. The area of the lesion was measured with the National Institutes of Health Image 1.55 (public domain software). The values reported represented the mean lesion area from 5 sections for each animal. The extent of atherosclerosis in mouse aorta was also determined with an "en face" method.8
Immunohistochemical Studies
Frozen sections were incubated with either a primary rat monoclonal antibody against mouse macrophage, clone MOMA-2 (BioSource International), or a primary goat polyclonal antibody against mouse Interleukin (IL)-10 (Pharmingen). Immunostaining was visualized as previously described.5
Analysis of the Ability of IL-10 Production by Macrophages
Resident peritoneal macrophages from both non-Tg and OPN-Tg mice obtained by peritoneal lavage with phosphate-buffered saline were treated with red cell lysis buffer and were incubated (105 macrophages per 100 µL) for 2 hours. The adherent fraction was incubated with lipopolysaccharide (LPS) (30 ng/mL) for 48 hours. Supernatant IL-10 was assayed with commercial ELISA kits (R&D Systems).
Statistical Analysis
The results are shown as the mean±SE. Two groups were compared with either Students t test or Student-Newman Keulss test with a one-way analysis of variance. P<0.05 was regarded as a significant difference.
| Results |
|---|
|
|
|---|
|
OPN Modulation of Macrophage IL-10 Production
The recent mice studies showed that mice deficient in OPN gene expression demonstrated an increase in production of IL-10,9 and showed that IL-10 overexpression can inhibit fatty-streak formation in the that were mice fed an atherogenic diet.10,11 Based on the findings of these reports, we performed immunohistochemical analysis. As shown in Figure 2A, non-Tg mice expressed detectable levels of IL-10 compared with OPN-Tg mice. To clarify the contribution of IL-10, we next examined the production of IL-10 in mice. Figure 2B shows the production of IL-10 by peritoneal macrophages from ONP-Tg and non-Tg mice. Figure 2B (left) shows the production of IL-10 without stimulation, in which both peritoneal macrophage groups released little IL-10. However, the IL-10 levels were less in the OPN-Tg mice than in the non-Tg mice (19.8±1.7 versus 34.0±2.9 pg/mL, P<0.01). Next, the induction of IL-10 production by LPS was performed. These results are shown in Figure 2B (right). The LPS-dependent IL-10 production of macrophages was significantly less in the OPN-Tg mice than in the non-Tg mice (81.8±7.4 versus 304.8±15.0 pg/mL, P<0.0001). These results show that OPN-Tg may decrease in the production of IL-10, especially under the inflammatory conditions, and a decrease of IL-10 may contribute to the susceptibility to atherosclerosis in OPN-Tg mice.
|
| Discussion |
|---|
|
|
|---|
A previous study showed the expression of OPN in peritoneal cells of OPN-Tg to significantly increase,13 and the present study demonstrated the production of IL-10 by macrophages from OPN-Tg to decrease. These results are compatible with the results of the previous study, in which OPN suppressed the LPS-dependent IL-10 response of peritoneal macrophages.9 We think the decrease in IL-10 must contribute to the development of fatty-streak lesions. Indeed, previous studies showed that IL-10 overexpression can inhibit fatty-streak formation in mice fed an atherogenic diet,10,11 and that IL-10 can induce endothelial cells to inhibit oxidized phospholipids-induced monocyte-endothelial interactions in vitro.10 These reports suggested that IL-10 might inhibit atherosclerosis. Although our findings suggest that the inhibition of IL-10 in OPN-Tg may play one of the most important roles in the development of atherosclerosis, we also believe that other factors most likely play a role in this phenomenon. For example, OPN has recently been classified as a T-helper 1 cytokine because of its ability to enhance interferon-
and IL-12 production and to diminish IL-10.9 The strong influence toward a T-helper 1 phenotype has previously been demonstrated in an atherosclerotic model,14,15 and therefore, we think that these factors may cause an increase of fatty-streak lesions in OPN-Tg mice. Further research is needed to clarify the mechanisms why OPN promotes atherogenesis.
Although the HDL levels decreased in the OPN-Tg, no significant difference was seen between OPN-Tg and non-Tg, and the total cholesterol levels tended to decrease in non-Tg. We thus believe that the HDL levels only slightly contributed to the increased fatty-streak lesions in OPN-Tg. The present study shows that early fatty-streak formation was promoted by OPN but the findings didnt show whether or not OPN has any effect on more mature and advanced lesions. We thus believe that the OPN overexpression must be bred onto the apoE-deficient background to determine whether or not OPN has any effect on advanced lesions. However, it remains important to determine whether OPN can be modulated by treatment, and whether or not such an approach can be used to modulate the immune responses and reduce atherosclerosis.
| Acknowledgments |
|---|
Received November 7, 2002; revision received December 18, 2002; accepted December 19, 2002.
| References |
|---|
|
|
|---|
2. Giachelli CM, Bae N, Almeida M, et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993; 92: 16861696.[Medline] [Order article via Infotrieve]
3. Ikeda T, Shirasawa T, Esaki Y, et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest. 1993; 92: 28142820.[Medline] [Order article via Infotrieve]
4. Shanahan CM, Cary NR, Metcalfe JC, et al. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994; 93: 23932402.[Medline] [Order article via Infotrieve]
5. Isoda K, Nishikawa K, Kamezawa Y, et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res. 2002; 91: 7782.
6. Hedrick CC, Castellani LW, Warden CH, et al. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem. 1993; 268: 2067620682.
7. Johnson RC, Chapman SM, Dong ZM, et al. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest. 1997; 99: 10371043.[Medline] [Order article via Infotrieve]
8. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res. 1995; 36: 23202328.[Abstract]
9. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (Osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000; 287: 860864.
10. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999; 85: e17e24.
11. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1999; 19: 28472853.
12. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res. 1996; 33: 181194.[Medline] [Order article via Infotrieve]
13. Iizuka J, Katagiri Y, Tada N, et al. Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest. 1998; 78: 15231533.[Medline] [Order article via Infotrieve]
14. Zhou X, Paulsson G, Stemme S, et al. Hypercholesterolemia is associated with a T helper 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest. 1998; 101: 17171725.[Medline] [Order article via Infotrieve]
15. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999; 145: 3343.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
M. Koshikawa, K. Aizawa, H. Kasai, A. Izawa, T. Tomita, S. Kumazaki, H. Tsutsui, J. Koyama, S. Shimodaira, M. Takahashi, et al. Elevated Osteopontin Levels in Patients With Peripheral Arterial Disease Angiology, February 1, 2009; 60(1): 42 - 45. [Abstract] [PDF] |
||||
![]() |
F. W. Kiefer, M. Zeyda, J. Todoric, J. Huber, R. Geyeregger, T. Weichhart, O. Aszmann, B. Ludvik, G. R. Silberhumer, G. Prager, et al. Osteopontin Expression in Human and Murine Obesity: Extensive Local Up-Regulation in Adipose Tissue but Minimal Systemic Alterations Endocrinology, March 1, 2008; 149(3): 1350 - 1357. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Mangan, A. V. Campenhout, C. Rush, and J. Golledge Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-{alpha} associated with induction of angiopoietin-2 Cardiovasc Res, December 1, 2007; 76(3): 494 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Scatena, L. Liaw, and C. M. Giachelli Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2302 - 2309. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gomez-Ambrosi, V. Catalan, B. Ramirez, A. Rodriguez, I. Colina, C. Silva, F. Rotellar, C. Mugueta, M. J. Gil, J. A. Cienfuegos, et al. Plasma Osteopontin Levels and Expression in Adipose Tissue Are Increased in Obesity J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3719 - 3727. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Tanaka, Y. Momiyama, R. Ohmori, A. Yonemura, M. Ayaori, M. Ogura, S. Sawada, M. Kusuhara, H. Nakamura, and F. Ohsuzu Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): e129 - e130. [Full Text] [PDF] |
||||
![]() |
P. Minoretti, C. Falcone, M. Calcagnino, E. Emanuele, M. P. Buzzi, E. Coen, and D. Geroldi Prognostic significance of plasma osteopontin levels in patients with chronic stable angina Eur. Heart J., April 1, 2006; 27(7): 802 - 807. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Karra, S. Vemullapalli, C. Dong, E. E. Herderick, X. Song, K. Slosek, J. R. Nevins, M. West, P. J. Goldschmidt-Clermont, and D. Seo Molecular evidence for arterial repair in atherosclerosis PNAS, November 15, 2005; 102(46): 16789 - 16794. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsuki, K. Isoda, R. Horai, A. Nakajima, Y. Aizawa, K. Suzuki, F. Ohsuzu, and Y. Iwakura Involvement of Tumor Necrosis Factor-{alpha} in the Development of T Cell-Dependent Aortitis in Interleukin-1 Receptor Antagonist-Deficient Mice Circulation, August 30, 2005; 112(9): 1323 - 1331. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Isoda, S. Sawada, N. Ishigami, T. Matsuki, K. Miyazaki, M. Kusuhara, Y. Iwakura, and F. Ohsuzu Lack of Interleukin-1 Receptor Antagonist Modulates Plaque Composition in Apolipoprotein E-Deficient Mice Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 1068 - 1073. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |